论文部分内容阅读
目的研究对比孟鲁司特钠联合舒利迭治疗支气管哮喘的临床效果及毒副作用。方法选取在我院接受治疗的78例支气管哮喘的患者,按平均分类法在其知情同意的情况下分为两组进行治疗,对照组给予舒利迭治疗,观察组在对照组的基础上给予孟鲁司特钠治疗,对两组的治疗效果、肺功能指标和不良反应进行观察。结果治疗效果方面,观察组与对照组相比差异明显P<0.05;具有统计学意义;两组不良反应的比较,观察组与对照组比较差异不明显P>0.05,无统计学意义;观察组患者的肺功能指标较对照组相比改善明显,两组比较差异明显P<0.05;有统计学意义。结论孟鲁司特钠联合舒利迭治疗支气管哮喘能够有效缓解患者的临床症状,改善患者的肺功能,且不良反应发生较少,值得临床推广。
Objective To compare the clinical effects and side effects of montelukast combined with seretide in the treatment of bronchial asthma. Methods A total of 78 patients with bronchial asthma who were treated in our hospital were enrolled in this study. Patients were divided into two groups according to the mean classification method. The control group was treated with seretide. The observation group was given on the basis of the control group Montelukast sodium treatment, the two groups of treatment, lung function indicators and adverse reactions were observed. Results Compared with the control group, the difference between the observation group and the control group was statistically significant (P <0.05). There was a statistically significant difference between the observation group and the control group. There was no significant difference between the observation group and the control group (P> 0.05) Patients with lung function index compared with the control group improved significantly, the difference between the two groups was significantly P <0.05; statistically significant. Conclusion Montelukast combined with seretide in the treatment of bronchial asthma can effectively alleviate the clinical symptoms of patients and improve the patient’s lung function, and fewer adverse reactions, is worthy of clinical promotion.